13:33:29 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 Ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2019-10-07 08:00:14
Oslo, Norway, 7 October 2019

Nordic Nanovector ASA (OSE: NANO) announces that it has signed a long-term
global supply agreement with a subsidiary of ITM Isotopen Technologien München
AG (ITM),  Isotope Technologies Garching GmbH (ITG) to ensure the supply of high
quality, no-carrier-added (n.c.a.) Lutetium-177, a key component of Betalutin®
([177]Lu-lilotomab-satetraxetan) for R&D, clinical and commercial uses.

ITM, a biotechnology and radiopharmaceutical group of companies and world-leader
in the development and production of radiopharmaceuticals and radionuclides for
the targeted treatment of cancers as well as for diagnostics, has been supplying
n.c.a. Lutetium-177 (EndolucinBeta®)* to Nordic Nanovector since 2010.

Marco Renoldi, Chief Operating Officer at Nordic Nanovector, said: "We are
pleased to extend our collaboration with a long-time and reliable partner such
as ITM. This global supply agreement is a key milestone in the implementation of
our CMC (Chemistry, Manufacturing and Controls) strategy for gaining regulatory
approval for Betalutin® and its subsequent commercial rollout, as it provides
certainty of continued supply of n.c.a. Lutetium-177 during clinical development
as well as after launch. The agreement with ITM, alongside other manufacturing
supply and development agreements in place with specialist manufacturers at all
stages of the manufacturing and supply chain for Betalutin® strengthens our
confidence in the ability to deliver a reliable and sustainable supply chain in
support of the launch of our lead asset."

Steffen Schuster, CEO of ITM, added: "Nordic Nanovector is one of our
longstanding partners and we are delighted that Nordic Nanovector has reaffirmed
their confidence through this long-term supply agreement for EndolucinBeta®.  In
addition to the development of our own pipeline, we have once again been able to
gain a strategic partner for the development of targeted radiopharmaceuticals in
Precision Oncology, thereby making a significant contribution to advancing a
promising treatment option for difficult-to-treat cancers. With our
manufacturing facilities around the world and our unrivaled logistics network,
we feel well equipped to reliably meet our partners' needs and to enter into
further strategic relationships."

*EndolucinBeta®, registered trademark of ITM´s EMA approved pharmaceutical
n.c.a. Lutetium-177.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com



About EndolucinBeta®

EndolucinBeta® is a radiopharmaceutical precursor with a half-life of 6.647
days, usable for radiolabeling of disease-specific carrier molecules. The active
substance of EndolucinBeta® is no-carrier-added (n.c.a.) Lutetium ([177]Lu)
chloride. No-carrier-added [177]Lu provides the highest specific activity of
more than 3,000 GBq/mg, whereby the day of calibration can be flexibly selected
by the customer. Due to its high specific activity, optimal preconditions for
efficient radiolabeling of biomolecules over its entire shelf-life of 9 days
after production are ensured. Furthermore EndolucinBeta® exhibits an
extraordinary level of radionuclidic purity. EndolucinBeta® does not contain
metastable [177m]Lu, thus, there is no need for cost intensive clinical waste
management. Marketing authorization holder of EndolucinBeta® is ITM's subsidiary
ITG.



About ITM Isotopen Technologien München

ITM Isotopen Technologien München AG is a privately held biotechnology and
radiopharmaceutical group of companies dedicated to the development, production
and global supply of targeted diagnostic and therapeutic radiopharmaceuticals
and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM
and its subsidiaries have established GMP manufacturing and a robust global
supply network of innovative, first-in-class medical radionuclides and generator
platforms for a new generation of targeted cancer diagnostics and therapies.
Furthermore, ITM is developing a proprietary portfolio and growing pipeline of
targeted treatments in various stages of clinical development, which address a
range of cancers such as neuroendocrine tumors and bone metastases. ITM's main
objectives, together with its scientific, medical and industrial collaboration
partners worldwide, are to significantly improve outcomes and quality of life
for cancer patients while at the same time reducing side-effects and improving
health economics through a new generation of Targeted Radionuclide Therapies in
Precision Oncology. For more information about ITM, please visit: www.itm.ag

Forward-looking statements

This press release contains certain forward-looking statements.  These
statements are based on management's current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.